Incorporation of uncertainty in health economic modelling studies Anthony O’HaganChristopher McCabeAndrew Willan Leading Article 17 September 2012 Pages: 529 - 536
Health utilities in Alzheimer’s disease and implications for cost-effectiveness analysis Peter J. Neumann Commentary 17 September 2012 Pages: 537 - 541
The economics of topical immunomodulators for the treatment of atopic dermatitis William AbramovitsMark BoguniewiczKuo B. Tong Review Article 17 September 2012 Pages: 543 - 566
Remission from depression Donald HanEdward C. Y. Wang Review Article 17 September 2012 Pages: 567 - 581
Bipolar disorder and health-related quality of life Dennis A. RevickiLouis S. MatzaAndrew Lloyd Review Article 17 September 2012 Pages: 583 - 594
Pharmacoeconomic evaluation of antidepressants Sheikh Usman IqbalMark Prashker Review Article 17 September 2012 Pages: 595 - 606
The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK Marco BarbieriJohn B. WongMichael Drummond Original Research Article 17 September 2012 Pages: 607 - 618
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease Michael SpencerAndrew H. BriggsLaureen Rance Original Research Article 17 September 2012 Pages: 619 - 637